Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer
Treatment for patients with metastatic colorectal cancer (mCRC) typically involves multiple lines of therapy with eventual development of treatment resistance. In this single arm, phase II study involving heavily pre-treated patients, the combination of sorafenib and capecitabine (SorCape) yielded a clinically meaningful progression free survival of 6.2 months with an acceptable toxicity profile. This oral doublet therapy is worthy of continued investigation for clinical use in patients with mCRC.